Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Spotlight Correspondence
  • Published:

Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia

Leukemia volume 17, pages 1414–1416 (2003)Cite this article

TO THE EDITOR

Chronic myeloid leukaemia (CML) is a clonal disorder resulting in marked expansion in cells of the myeloid lineage, which invariably progresses in defined stages from the initial chronic phase to accelerated phase, and then blast crisis or acute leukaemia. The translocation resulting in the Philadelphia (Ph) chromosome leads to the production of BCR-ABL tyrosine kinase, and is present in virtually all patients. Although αIFN therapy successfully induces a haematological and cytogenetic response in CML, the associated side effects have been considerable.1 Once progression to acute leukaemia has occurred from CML, standard chemotherapy results in only a limited response.2

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

References

  1. Larson R . Imatinib (STI571, Gleevecâ„¢) as initial therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia (CML): results of a randomized phase III study vs interferon-alfa+cytarabine (IFN+AraC). Blood 2002; 100: 2a.

    Google Scholar 

  2. Sawyers C, Hochhaus A, Feldman E, Goldman J, Miller C, Ottmann O et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539.

    Article  CAS  Google Scholar 

  3. Druker B, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.

    Article  CAS  Google Scholar 

  4. Demetri G, von Mehren M, Blanke C, Van den Abbeele A, Eisenberg B, Roberts P et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472–480.

    Article  CAS  Google Scholar 

  5. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.

    Article  CAS  Google Scholar 

  6. Eming S, Whitsitt J, Krieg L, Morgan J, Davidson J . Particle-mediated gene transfer of PDGF isoforms promotes wound repair. J Invest Dermatol 1999; 112; 297–302.

    Article  CAS  Google Scholar 

  7. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed R, Heldin C et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 2001; 61: 2929–2934.

    CAS  PubMed  Google Scholar 

  8. Ebnoether M, Stentoft J, Ford J, Buhl L, Gratwohl A . Cerebral oedema as a possible complication of treatment with imatinib. Lancet 2002; 359: 1751–1752.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematological Medicine, GKT School of Medicine, King's College Hospital, Denmark Hill Campus, London, UK

    D Milojkovic & G J Mufti

  2. Department of Dermatology, King's College Hospital, London, UK

    K Short, D Creamer & A W P du Vivier

  3. Department of Histopathology, GKT School of Medicine, Denmark Hill Campus, London, UK

    J R Salisbury

Authors
  1. D Milojkovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Short
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J R Salisbury
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Creamer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A W P du Vivier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G J Mufti
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milojkovic, D., Short, K., Salisbury, J. et al. Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia. Leukemia 17, 1414–1416 (2003). https://doi.org/10.1038/sj.leu.2402991

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402991

This article is cited by

Search

Advanced search

Quick links